Curanex Pharmaceuticals Inc. (CURX) Stock Price & Analysis

CURX Stock Chart & Stats

$5.16$0.22(4.45%)

At close: Oct 30 4:00 PM EDT

Day’s Range: $5.08 - $5.36
52-Week Range: $3.56 - $14.13
Previous Close: $4.94
Volume: 113.47K
Average Volume (3M): 19.88K
Market Cap: $8.09M
Enterprise Value: $5.79T
Total Cash (Recent Filing): $2.94M
Total Debt (Recent Filing): $276.36K
Price to Earnings (P/E): ―
Beta: 0.54
Next Earnings: N/A
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Curanex Pharmaceuticals Inc. News

Curanex Pharmaceuticals Faces IPO-Related Securities Litigation

Curanex Pharmaceuticals Inc. ( ($CURX) ) just unveiled an announcement. Curanex Pharmaceuticals Inc., a drug developer that went public via an August 2025 initial public offering, relies on capital markets

1w ago8K CURX

Curanex Pharmaceuticals Regains Nasdaq Compliance After Reverse Split

Curanex Pharmaceuticals Inc. ( ($CURX) ) just unveiled an announcement. On November 5, 2025, Curanex Pharmaceuticals Inc. was notified by Nasdaq that its common stock had failed to meet the

1M ago8K CURX

Curanex Pharmaceuticals Inc trading halted, news pending

19:50 EDT Curanex (CURX) Pharmaceuticals Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks

2M agoCURX

Curanex Announces Reverse Stock Split to Maintain Nasdaq Listing

Curanex Pharmaceuticals Inc. ( ($CURX) ) has provided an announcement. On May 31, 2026, Curanex’s board and on June 11, 2026, a majority of voting shareholders approved a reverse stock

2M ago8K CURX

Curanex Advances Phyto-N Program and Expands Indications

An announcement from Curanex Pharmaceuticals Inc. ( ($CURX) ) is now available. On May 14, 2026, Curanex reported first-quarter 2026 progress on Phyto-N, highlighting completion of GMP-compliant pilot-scale manufacturing in

5M ago8K CURX

Curanex Granted Nasdaq Extension to Regain Listing Compliance

Curanex Pharmaceuticals Inc. ( ($CURX) ) has shared an update. On November 5, 2025, Curanex Pharmaceuticals Inc. was notified by Nasdaq that its common stock had closed below the $1.00

5M ago8K CURX

Curanex highlights patient case study in treatment of cancer cachexia

Curanex (CURX) highlighted a patient case study that management believes further supports the company’s strategic interest in treatment of cancer cachexia. The company said, “The case involved “Johnny,” a senior

6M agoCURX

Curanex Adds Cancer Cachexia to Core Drug Pipeline

The latest update is out from Curanex Pharmaceuticals Inc. ( ($CURX) ). On April 2, 2026, Curanex Pharmaceuticals Inc. announced it is expanding its drug development pipeline to make cancer

7M ago8K CURX

Curanex completes dose-range finding toxicology study of Phyto-N

Curanex (CURX) Pharmaceuticals announced the successful completion of a dose-range finding toxicology study of its lead botanical drug candidate, Phyto-N, conducted in Sprague-Dawley rats and dogs. The study evaluated repeat-dose

7M agoCURX

Curanex appoints two research experts to board of directors

Curanex Pharmaceuticals (CURX) announced the appointment of two life sciences research experts to the Company’s Scientific Advisory Board. Daniel Pascheles is Former CEO and Partner at Molekule Consulting. Nicholas Meanwell

7M agoBMY CURX

Curanex Formalizes Long-Term Executive Employment and Compensation Agreements

Curanex Pharmaceuticals Inc. ( ($CURX) ) has provided an announcement. On March 2, 2026, Curanex Pharmaceuticals Inc. approved a four-year executive employment agreement for CEO and President Jun Liu, effective

8M ago8K CURX

Curanex announces formation of Scientific Advisory Board

Curanex (CURX) Pharmaceuticals announced the formation of a new Scientific Advisory Board, reporting to and supporting the executive team and Board of Directors of Curanex. The Scientific Advisory Board shall

8M agoCURX

Curanex provides operational update on regulatory milestones

Curanex (CURX) Pharmaceuticals announced the completion of a Good Manufacturing Practice-compliant pilot-scale batch of its lead botanical drug candidate, Phyto-N. This pilot marks a key manufacturing milestone in preparation for

8M agoCURX

Curanex Pharmaceuticals Appoints New Chief Financial Officer

The latest announcement is out from Curanex Pharmaceuticals Inc. ( ($CURX) ). On December 31, 2025, Curanex Pharmaceuticals Inc. announced that Chief Financial Officer and Treasurer Haiyan Yang resigned effective

10M ago8K CURX

CURX FAQ

What was Curanex Pharmaceuticals Inc.’s price range in the past 12 months?

Curanex Pharmaceuticals Inc. lowest stock price was $3.56 and its highest was $14.13 in the past 12 months.

What is Curanex Pharmaceuticals Inc.’s market cap?

Curanex Pharmaceuticals Inc.’s market cap is $8.09M.

When is Curanex Pharmaceuticals Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

Is Curanex Pharmaceuticals Inc. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Curanex Pharmaceuticals Inc. pay dividends?

Curanex Pharmaceuticals Inc. does not currently pay dividends.

What is Curanex Pharmaceuticals Inc.’s EPS estimate?

Curanex Pharmaceuticals Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Curanex Pharmaceuticals Inc. have?

Curanex Pharmaceuticals Inc. has 1,568,241 shares outstanding.

Which hedge fund is a major shareholder of Curanex Pharmaceuticals Inc.?

Currently, no hedge funds are holding shares in CURX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description